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Abstract
Purpose—SWI has significantly increased our sensitivity in detecting hemorrhagic brain lesions. 
We sought to explore the prevalence of intra-tumoral hemorrhage as detected by SWI in brain 
metastases from melanoma and breast cancer.
Methods—Lesions with a size of 0.1 cm3 were categorized as micro-metastases while larger 
lesions were categorized as macro-metastases. SWI findings on locations corresponding to 
enhancing lesions were categorized as either positive or negative based on presence/absence of 
signal dropout. The percentage of SWI positivity was then estimated as a function of lesion size. 
Two-tailed Fisher's exact test was performed to examine differences in the contingency tables.
Results—MRI studies from 73 patients with 1,173 brain metastases which enhanced on post-
contrast T1-weighted imaging (T1WI) were selected for analysis. Of these lesions, 952 had SWI 
data available, and 342 out of 952 were micro-metastases. Only 10 of the 342 micro-metastases 
and 410 of the 610 macro-metastases were SWI positive (67.2%, p-value of < 0.0001). When 
examined by tumor type, 76.9% (melanoma) versus 55.6% (breast cancer) were SWI positive (p-
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value < 0.0001), regardless of tumor size. All melanoma lesions (8/8) and only 1 out of 15 breast 
cancer lesions larger than 1.5 cm3 were SWI positive.
Conclusion—Using combined SWI and contrast-enhanced high-resolution T1 imaging we found 
that presence of intra-tumoral brain hemorrhage is uncommon in micro-metastases but common in 
metastases > 0.1 cm3 from breast cancer or melanoma. Large metastases commonly harbored 
hemorrhage and this occurred more frequently in patients with melanoma than with breast cancer.
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Introduction
Spontaneous intracerebral hemorrhage is a potentially devastating disease that can be the 
end result of various conditions, including malignancies. Although acute hemorrhage can be 
the presenting sign of a primary brain malignancy, distinct metastatic brain tumors may have 
a higher propensity (e.g. thyroid, choriocarcinoma, melanoma, and renal cell carcinoma) or a 
higher prevalence (e.g. breast and lung cancer) of intratumoral hemorrhage than primary 
brain tumors. [1] Apart from the obvious potentially catastrophic consequences of 
symptomatic intra-tumoral brain hemorrhage, little is known about the biology and 
prognostic implications of occult intracranial hemorrhage. It has been recently shown that 
histopathologic detection of hemorrhage in routine hematoxylin and eosin-stained sections 
from patients who have undergone craniotomy for melanoma and breast cancer brain 
metastases can be an adverse prognostic factor. [2, 3] Given the obvious limitations of 
craniotomy-based research to generalize findings, non-invasive (i.e. imaging) detection of 
intra-tumoral hemorrhage across various cancer types, in particular the association between 
clinico-pathologic and radiographic features (e.g. contrast enhancement, number and size of 
metastases), holds promise to refine prognosis and improve treatment decisions.
Development of the susceptibility weighted imaging (SWI) sequence has significantly 
increased our sensitivity to noninvasively detect the venous vasculature, blood products, and 
changes in iron content of brain lesions. [4] In the case of brain tumors, SWI sequence 
complements, or even supersedes, tumor detection and other characteristics, such as 
boundaries, architecture of tumor vasculature, and presence of blood products identified by 
conventional T1-weighted contrast-enhanced imaging. [5] Due to the distinct intralesional 
susceptibility signal(s) within brain lesions, SWI in conjunction with conventional MRI has 
been previously used in glioma grading as well as in the differential diagnosis of enhancing 
brain lesions. [6-8] With respect to solid tumors, SWI has been recently used to understand 
the primary tumor characteristics of patients with clear-cell type renal cell [9-10], 
hepatocellular [11], and prostate carcinomas. [12] A single study investigated the sensitivity 
of detecting hemorrhage in brain metastases from patients with lung cancer compared to 
conventional contrast enhanced MRI sequences. [13] In this study, we sought to explore the 
prevalence of intra-tumoral hemorrhage as detected by SWI in patients with brain metastases 
from melanoma and breast cancer, and to correlate it with tumor size.
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This retrospective study was approved by our Institutional Review Board (IRB). Patients 
were identified from the Outpatient Melanoma and Breast Cancer Clinics database, where 
they were receiving clinical care and follow up. Enrolled subjects had histologically 
confirmed melanoma or breast cancer, and brain MRI imaging studies at the time of the 
initial diagnosis of brain metastases. All contrast-enhancing brain lesions were presumed to 
be metastatic foci. Patients with a history of prior brain surgery or radiation were excluded 
due to the potential for local treatment-induce hemorrhage that would yield signal 
abnormalities on SWI. Only MRI studies that were performed at the time of diagnosis of 
brain metastases were included in the analysis. Additionally, MRI studies were reviewed for 
image quality, and studies with motion and other artifacts were excluded from the analysis.
Image Acquisition
All patients were scanned at 3T using a standard 12-channel phase array body-matrix coil. 
Contrast-enhanced images were obtained immediately following intravenous administration 
of 0.1 ml/kg gadobenate dimeglumine (MultiHance®, Bracco Imaging, Princeton, NJ) with 
a T1-weighted fat-suppressed spoiled gradient echo sequence as follows: Axial gradient 
echo (GRE) T1-weighted imaging [TR/TE/TI (9.7/4.0/300) field of view, 240-mm; voxel 
size, 1.3× 1.3 × 1.2-mm; slice thickness, 1.2-mm; flip angle, 15. SWI were obtained before 
the administration of contrast as follows: (TR/TE (28/20), field of view, 240-mm; voxel size, 
1 × 1 × 1.5-mm; matrix size, 192×256; reconstructed slice thickness, 6 mm (obtained from 
four 1.5 mm thick slices), flip angle, 20).
Image Analysis
All contrast-enhancing brain lesions by conventional MRI sequences were identified for 
each patient in a picture archiving and communication system (PACS) workstation and were 
considered brain metastases based on consensus opinion of the medical oncologist and 
neuroradiologist. Readers were blinded to the cancer type (i.e. melanoma versus breast 
cancer). For assessment of individual tumor volumes, the maximal and orthogonal diameters 
of each lesion were measured in the axial plane. The depth of each lesion was then measured 
by counting the number of slices where each lesion was visible on the T1 sequence. An 
ellipsoid volume, V, for each lesion was then calculated through the following equation:
Where a, b, c, is the maximal diameter, orthogonal diameter and depth of each lesion, 
respectively. Micro-metastases were defined as contrast-enhancing lesions ≤ 0.1 cm3 in size. 
Each of the brain metastases was classified as hemorrhagic or not by comparison with the 
best matching SWI slice.
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A two-tailed Fisher exact test was performed to examine differences in the contingency 
tables (breast versus melanoma brain metastases, hemorrhage versus non-hemorrhage).
Results
Overall 1,173 contrast-enhancing brain lesions were identified in 73 patients. Of these 
lesions, 952 had SWI sequence data available for analysis. 38 of the subjects had breast 
cancer (467 analyzed lesions) and 35 had melanoma (485 analyzed lesions). Only 10 of 342 
micro-metastases had SWI abnormalities, while 410 of 610 (67.2%) larger lesions were SWI 
positive and thus hemorrhagic (p-value < 0.0001). When examined by primary tumor type, 
76.9% (melanoma) versus 55.6% (breast cancer) were SWI positive (p-value < 0.0001). All 
melanoma lesions (8/8) larger than 1.5 cm3 were SWI positive, while 14 of 15 similar breast 
cancer lesions were SWI negative. (Fig. 1)
Discussion
The development of hemorrhage within brain metastases has been attributed to the presence 
of abnormal, leaky vessels within the tumor. Histological studies have identified common 
features associated with hemorrhage, including tumor necrosis, vessel-wall hyalinization, 
necrosis of the vessel walls and vessel rupture. [14] The expression of vascular endothelial 
growth factor (VEGF) and matrix-metalloproteinases (MMP -2 and -9) has also being 
associated with the presence of hemorrhage. Rapid growth of a tumor induces hypoxia 
which in turn stimulates VEGF production. The MMP family of proteinases plays the 
important role of degrading the extra-cellular membrane and microvascular integrity, and in 
turn, likely further weakens the blood vessel walls. Various explanations for the presence of 
hemorrhage have been proposed ranging from direct invasion to venous thrombosis, while 
choriocarcinoma metastases are considered a special case due to the direct invasion of 
vessels by the tumor. [15]
Our study investigated the incidence of intratumoral brain hemorrhages as detected by SWI 
in untreated brain metastases from cohorts of patients (≥ 35 patients each) with metastatic 
melanoma and breast cancer. Identification of intra-tumoral hemorrhage in metastatic brain 
tumors is clinically important for treatment decisions. The increased sensitivity of SWI 
sequence is due to the use of the phase signal altered by the presence of deoxyhemoglobin 
and hemosiderin deposited within metastases. Previous histopathologic analysis suggests 
that intra-tumoral hemorrhage may be prognostic in melanoma but not in breast brain 
metastases and that non-invasive identification of hemorrhage may also have disease-
specific prognostic implications. [2, 3] The higher incidence of hemorrhage seen in 
melanoma as opposed to breast brain metastases seen in our patients is in agreement with a 
previous study that predominantly focused on quantification of intra-tumoral susceptibility 
signals in SWI sequences obtained in patients who underwent brain MRI for metastatic brain 
tumors from melanoma, breast cancer, and lung cancer as well as with previous analysis of 
hemorrhage and other histopathologic factors in representative tumor sections from large 
cohorts of specimens that were collected as part of craniotomies for brain metastases from 
melanoma or breast cancer. [16]
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Our second aim was to correlate tumor size with presence of hemorrhage on SWI. It has 
been suggested that, despite the unique biology that may account for the increased 
propensity of melanoma to bleed as compared with breast brain metastases, other factors 
such as tumor size may play a role. [17] Although in our patients incidence of hemorrhage 
was higher in larger size tumors (>1.5 cm3) and was significantly lower to absent in micro-
metastases irrespective of tumor type, we again identified that for a given tumor size, 
melanomas metastatic to the brain had a higher incidence of hemorrhage compared to breast 
brain metastases.
Overall, the relatively low prevalence of SWI detectable hemorrhage in micro-metastases 
would limit its utility in detecting micro-metastases when used independently. However, in 
patients with impaired renal function or contrast agent allergies, SWI does offer the potential 
to detect metastases without the use of contrast. Others have proposed its use in attempting 
to distinguish between primary and metastatic brain tumors, and understanding the 
prevalence of SWI abnormalities in metastases would assist in understanding its predictive 
value. [18] The difference in hemorrhage prevalence also points to different biological 
mechanisms for brain invasion by the metastases and emphases the need for a better 
understanding of the underlying pathophysiology. [2]
Caveats in our study include the lack of histopathologic proof that all enhancing lesions 
were indeed metastases. Furthermore, we did not compared the results of SWI with other 
sequences, such as pre-contrast T1 and gradient echo images, as it is known that SWI is 
superior to these sequences in detecting hemorrhage. Also, we did not seek prognostic or 
survival information or correlated our findings with genetics/biological status of the lesions.
Conclusions
Using SWI and contrast enhanced high resolution T1 imaging we found that presence of 
hemorrhage is uncommon in micro-metastases but common in larger metastases regardless 
of primary source, melanoma vs. breast cancer. Larger metastases from these two primaries 
commonly harbored hemorrhage and this occurred more often with melanoma than with 
primary breast cancer.
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(a) Post contrast T1 image shows multiple enhancing lesions in patient with known 
metastatic melanoma. (b) Corresponding SWI demonstrates low signal intensity in the larger 
right mesial temporal lesion, the small left amygdala lesion and in the smaller right occipital 
lesion (arrow) which is difficult to appreciate on A due to overlying artifacts from flow in 
the posterior sagittal sinus.
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